The Association of Urinary Sclerostin and Renal Magnesium Handling in Type 2 Diabetic Patients with Chronic Kidney Disease

Introduction: Sclerostin could enhance renal excretion of calcium (Ca) and phosphate (P). The association between sclerostin and magnesium (Mg) has not yet discovered. In patients with type 2 diabetes mellitus (T2DM) or chronic kidney disease (CKD), higher serum sclerostin and altered renal excretion of Ca, P, and Mg were detected. Therefore, we tried to evaluate if there was any association between sclerostin and fractional excretion of Ca, P, and Mg (FeCa, FeP, and FeMg) in T2DM with CKD. Methods: In this prospective cohort study, 43 T2DM patients without CKD or with CKD stage 1–5 were enrolled. Values of parameters, including serum and urine sclerostin, were collected at baseline and 6 months later. For baseline data, the Mann-Whitney U test, χ2 test, or Spearman’s correlation were used. For multivariate repeated measurement analysis, generalized estimating equation (GEE) model was utilized. Results: Patients with lower estimated glomerular filtration rate had higher serum sclerostin, FeP, FeMg, and lower FeCa. By correlation analysis, serum sclerostin was negatively associated with FeCa (p = 0.02) and positively associated with FeP (p = 0.002). The urine sclerostin to creatinine ratio (Uscl/Ucre) was positively correlated with FeP (p = 0.007) and FeMg (p = 0.005). After multivariate analyses by GEE model, serum sclerostin was still inversely associated with FeCa, while Uscl/Ucre was significantly associated with FeMg. On the other hand, FeP lost its associations with serum sclerostin or Uscl/Ucre. Conclusion: In our study population of T2DM patients with or without CKD, the inverse correlation between serum sclerostin and FeCa could not be explained by the calciuric effect of sclerostin. In addition, a newly discovered positive association between urinary sclerostin and FeMg indicated a possible role of urinary sclerostin in regulating renal Mg handling especially over distal convoluted tubules.

[1]  Jo-Yen Chao,et al.  Serum sclerostin levels are positively related to bone mineral density in peritoneal dialysis patients: a cross-sectional study , 2019, BMC Nephrology.

[2]  Z. Massy,et al.  Differential Determinants of Tubular Phosphate Reabsorption: Insights on Renal Excretion of Phosphates in Kidney Disease , 2018, American Journal of Nephrology.

[3]  A. Yu,et al.  Magnesium Handling in the Kidney. , 2018, Advances in chronic kidney disease.

[4]  P. Xue,et al.  Role of sclerostin and dkk1 in bone remodeling in type 2 diabetic patients , 2018, Endocrine research.

[5]  Yen-Cheng Chen,et al.  Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients , 2016, Medicine.

[6]  P. Evenepoel,et al.  Sclerostin and DKK1: new players in renal bone and vascular disease. , 2015, Kidney international.

[7]  O. Lee,et al.  Circulating Wnt/β-catenin signalling inhibitors and uraemic vascular calcifications. , 2015, Nephrology, Dialysis and Transplantation.

[8]  M. Chonchol,et al.  Renal control of calcium, phosphate, and magnesium homeostasis. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[9]  H. Ryoo,et al.  Hyperglycemia increases the expression levels of sclerostin in a reactive oxygen species- and tumor necrosis factor-alpha-dependent manner , 2015, Journal of periodontal & implant science.

[10]  Sudhaker D. Rao,et al.  Sclerostin: recent advances and clinical implications , 2014, Current opinion in endocrinology, diabetes, and obesity.

[11]  Jocelyn T. Compton,et al.  A review of osteocyte function and the emerging importance of sclerostin. , 2014, The Journal of bone and joint surgery. American volume.

[12]  Rajiv Ranjan Kumar,et al.  Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis. , 2014, Journal of the American Society of Nephrology : JASN.

[13]  M. Inaba,et al.  Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. , 2014, The Journal of clinical endocrinology and metabolism.

[14]  H. Ryoo,et al.  TNF‐α Upregulates Sclerostin Expression in Obese Mice Fed a High‐Fat Diet , 2014, Journal of cellular physiology.

[15]  Hui Chen,et al.  The effects of diabetes mellitus and diabetic nephropathy on bone and mineral metabolism in T2DM patients. , 2013, Diabetes research and clinical practice.

[16]  T. Craig,et al.  Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium , 2013, Proceedings of the National Academy of Sciences.

[17]  Y. Vanrenterghem,et al.  Evidence in Favor of a Severely Impaired Net Intestinal Calcium Absorption in Patients with (Early-Stage) Chronic Kidney Disease , 2012, American Journal of Nephrology.

[18]  Y. Nabeshima,et al.  Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. , 2012, Kidney international.

[19]  P. Messa,et al.  Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients , 2012, Clinical kidney journal.

[20]  A. Branscum,et al.  Sclerostin and Dickkopf-1 in renal osteodystrophy. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[21]  D. Molony,et al.  Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations. , 2011, Advances in chronic kidney disease.

[22]  P. Messa,et al.  Pathophysiology of Calcium and Phosphate Metabolism Impairment in Chronic Kidney Disease , 2009, Blood Purification.

[23]  Jeffrey M. Miller,et al.  Hypomagnesemia in patients with type 2 diabetes. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[24]  L. Lai,et al.  Increased renal calcium and magnesium transporter abundance in streptozotocin-induced diabetes mellitus. , 2006, Kidney international.

[25]  V. Vallon,et al.  Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. , 2005, The Journal of clinical investigation.

[26]  H. Garland,et al.  Renal calcium and magnesium handling in experimental diabetes mellitus in the rat. , 1990, Acta endocrinologica.

[27]  R. Marculescu,et al.  Renal elimination of sclerostin increases with declining kidney function. , 2014, The Journal of clinical endocrinology and metabolism.

[28]  P. Rowe.  Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. , 2012, Critical reviews in eukaryotic gene expression.

[29]  D. Cole,et al.  Magnesium transport in the renal distal convoluted tubule. , 2001, Physiological reviews.